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http://www.biomedcentral.com/1471-2369/15/15RESEARCH ARTICLE Open AccessEconomic evaluations of angiotensin-converting
enzyme inhibitors and angiotensin II receptor
blockers in type 2 diabetic nephropathy:
a systematic review
Yunyu Huang1,2,3*, Qiyun Zhou1, Flora M Haaijer-Ruskamp2 and Maarten J Postma1Abstract
Background: Structured comparison of pharmacoeconomic analyses for ACEIs and ARBs in patients with type 2
diabetic nephropathy is still lacking. This review aims to systematically review the cost-effectiveness of both ACEIs
and ARBs in type 2 diabetic patients with nephropathy.
Methods: A systematic literature search was performed in MEDLINE and EMBASE for the period from November 1,
1999 to Oct 31, 2011. Two reviewers independently assessed the quality of the articles included and extracted data.
All cost-effectiveness results were converted to 2011 Euros.
Results: Up to October 2011, 434 articles were identified. After full-text checking and quality assessment, 30 articles
were finally included in this review involving 39 study settings. All 6 ACEIs studies were literature-based evaluations
which synthesized data from different sources. Other 33 studies were directed at ARBs and were designed based
on specific trials. The Markov model was the most common decision analytic method used in the evaluations. From
the cost-effectiveness results, 37 out of 39 studies indicated either ACEIs or ARBs were cost-saving comparing with
placebo/conventional treatment, such as amlodipine. A lack of evidence was assessed for valid direct comparison of
cost-effectiveness between ACEIs and ARBs.
Conclusion: There is a lack of direct comparisons of ACEIs and ARBs in existing economic evaluations. Considering
the current evidence, both ACEIs and ARBs are likely cost-saving comparing with conventional therapy, excluding
such RAAS inhibitors.Background
Approximately one fourth to one third of patients with
diabetes mellitus develop renal manifestations [1-4]. Clin-
ical stages of diabetic nephropathy are generally catego-
rized into stages based on the values of urinary albumin
excretion: microalbuminuria (MiA) and macroalbumi-
nuria (MaA) [5]. The prevalence of MiA and MaA in type
2 diabetes is as high as 37–40% in western countries and
57.4–59.8% in Asian countries [6-8]. 20–40% of type 2
diabetic patients with MiA progress to overt nephropathy,* Correspondence: y.huang02@umcg.nl
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reproduction in any medium, provided the orand by 20 years after onset of overt nephropathy, about
20% will have progressed to end-stage renal diseases
(ESRD) [9]. Because of the large prevalence, diabetes has
become the most common single cause of ESRD in the
U.S. and Europe [10,11]. As therapies and interventions
for coronary artery disease continue to improve, more pa-
tients with type 2 diabetes may be expected to survive
long enough to develop renal failure.
In developed countries, ESRD is a major cost driver
for health-care systems, with annual growth of dialysis
programs ranging between 6% and 12% over the past
two decades and continuing to grow, particularly in de-
veloping countries [12]. Although there are no definitive
cure solutions, there is good evidence that adequate
treatment can delay or prevent the progress of diabetic
nephropathy including strict control of glycaemia, earlyLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and lipid-lowering therapy [13]. Targeting renin–angio-
tensin–aldosterone system (RAAS) is the most effective
way to delay renal disease progression. Treatment guide-
lines therefore recommended angiotensin-converting
enzyme inhibitors (ACEIs) and angiotensin II receptor
blockers (ARBs) as the first-choice agents for treating
nephropathy in diabetic patients [14].
Both ACEIs and ARBs target the RAAS and have
proven their renal protective effects in diabetic patients in
various clinical trials. One disadvantage of ACEIs [15-17]
in comparison with ARBs is the higher risk of dry cough
while significant differences in effectiveness between these
two drug classes have not been shown convincingly al-
though ARBs have been more thoroughly investigated
in controlled settings in the recent decade providing rela-
tively high levels of evidence. Often clinical practice
guidelines recommend both ACEIs and ARBs in diabetic
patients with or even without (micro)albuminuria [18].
Pharmacoeconomic evaluations of ACEIs and ARBs have
been widely applied based on clinical trials’ results. The
pharmacoeconomic results of ARBs have been reviewed
previously [19-26]. ARBs were suggested to be cost saving
in type 2 diabetic patients with nephropathy versus
conventional therapy, largely due to the high costs of treat-
ment of ESRD. However, a systematic review of cost-Table 1 Search terms for systematic review
Search terms MEDLINE
Drug Mesh: Angiotensin-Converting Enzyme Inhibitors;
Angiotensin Receptor Antagonists;
TIAB (Title and Abstract): ACEIs; ARBs; ACEI; ARB; ren
angiotensin system inhibitor*a; renin angiotensin
aldosterone system inhibitor*; ACE inhibitor*; RAS
inhibitor*; RAAS inhibitor*; angiotensin converting
enzyme inhibitor*; renin angiotensin system inhibitor*
angiotensin receptor blocker*; Losartan; Candesartan;
Valsartan; Irbesartan; Telmisartan; Eprosartan; Olmesart
Azilsartan; Benazepril; Captopril; Enalapril; Fosinopril;




Mesh: Diabetes Mellitus, Type 2; Diabetic Nephropath
Kidney Failure, Chronic;




Mesh: Economics, Pharmaceutical; Costs and Cost Analy
Drug Costs; Cost Savings; Cost of Illness; Cost-Benefit Ana
TIAB: cost effect*; cost utility; cost benefit*; economic
evaluation*; cost analys*
Search Strategy (“Drug Term 1”[Mesh] OR “Drug Term 2”[TIAB] …) AN
(“DN Term 1”[Mesh] OR “DN Term 2”[TIAB] …) AND
(“EE Term 1”[Mesh] OR “EE Term 2”[TIAB] …)
a: An asterisk (*) following the word is the wildcard character, which means to sear
can be found in MEDLINE.effectiveness results of ACEIs in type 2 diabetic patients
with renal disease is still lacking. In addition, the need of a
structured pharmacoeconomic comparison of the ACEIs
with ARBs is pointed out by some researchers [21,26].
The aim of this study is to address the similarities and
differences in cost-effectiveness analyses for both ACEIs
and ARBs in type 2 diabetic patients with nephropathy. In
particular, three objectives are addressed: 1) to summarize
the cost-effectiveness of ACEIs; 2) to update the cost-
effectiveness of ARBs; 3) to compare the characteristics of
different economic evaluations and analyze potential dif-
ferences and similarities in the cost-effectiveness between
the two drug classes reviewed.
Methods
Literature search strategy
A systematic literature search was performed in MEDLINE
and EMBASE for the period November 1, 1999 to Oct 31,
2011. The key words (MeSH headings in MEDLINE,
EMtree terms in EMBASE and other text terms) in-
cluded were (Table 1):
– Indicating target drugs, the variations in and
abbreviations of ACEIs and ARBs were searched,
such as ‘angiotensin receptor antagonists’, ‘renin
angiotensin aldosterone system inhibitors’, andEMBASE





ab,ti (Abstract and Title): angiotensin receptor blocker;
angiotensin receptor blockers; arb; arbs; ace inhibitor; ace
inhibitors; angiotensin converting enzyme inhibitor; angiotensin
converting enzyme inhibitors; angiotensin converting enzyme
(ace) inhibitor; angiotensin converting enzyme (ace) inhibitors;
acei; aceis; renin angiotensin system inhibitor; renin angiotensin
system inhibitors; renin angiotensin system (ras) inhibitor; renin
angiotensin system (ras) inhibitors; ras inhibitor; ras inhibitors; renin
angiotensin aldosterone system inhibitor; renin angiotensin
aldosterone system inhibitors; raas inhibitor; raas inhibitors;
losartan; candesartan; valsartan; irbesartan; telmisartan; eprosartan;
olmesartan; azilsartan; benazepril; captopril; enalapril; fosinopril;
lisinopril; moexipril; perindopril; quinapril; ramipril; trandolapril;
ies; EMtree: non insulin dependent diabetes mellitus; diabetic
nephropathy;
ab,ti: diabetic nephropathy; diabetic nephropathies; diabetic renal




EMtree: pharmacoeconomics; economic evaluation; drug cost; cost
control; cost of illness; cost benefit analysis; cost effectiveness analysis;
ab,ti: cost effectiveness; cost utility; cost benefit; economic
evaluation; economic evaluations; cost analys;
D (‘Drug Term 1’/exp OR ‘Drug Term 2’:ab,ti …) AND
(‘DN Term 1’/exp OR ‘DN Term 2’:ab,ti …) AND (‘EE Term 1’/exp
OR ‘EE Term 2’:ab,ti …) NOT [medline]/limb
ch in MEDLINE for all terms that begin with a word; b: To exclude articles that
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including 10 specific ACEIs (such as captopril,
enalapril, etc.) and 8 ARBs (such as losartan,
irbesartan, etc.).
– Indicating diabetic nephropathy, key words were
limited to ‘type 2 diabetes’ and its variations.
Variations of nephropathy were combined with
diabetes, such as ‘diabetic renal diseases’ or ‘diabetic
kidney diseases’.
– Indicating economic evaluations, various key words
relating to different evaluation types,
pharmacoeconomics, cost of drugs and cost analysis
were searched, including ‘cost-effectiveness analysis’
(CEA), ‘cost-utility analysis’ (CUA), ‘cost-benefit
analysis’ (CBA), and ‘cost savings’, etc.
The references of identified articles were manually
screened for relevant economic evaluations not identi-
fied in the above-mentioned searches (snowballing).
Study selection
Inclusion criteria for the review were as follows (following
the PICOS-design):
– Population: patients in studies had to have type 2
diabetes with symptoms of renal diseases;
– Interventions and Comparators: studies must
examine an ACEI- or ARB-based treatment regimen
for the progression of diabetic nephropathy
compared with regimens that did not include these
medications, or if available, compare ACEIs with
ARBs directly;
– Outcomes: clinical outcomes should be relevant to
renal disease symptoms, including overt diabetic
nephropathy, ESRD (kidney transplantation or
dialysis), all-cause mortality, etc.; and
– Study design: studies had to be original economic
evaluations.
Other criteria concerned that studies had to have been
published as full-length articles and were peer-reviewed
for English-language journals.
Study selection was performed in three rounds. First, ti-
tles and abstracts of searched articles were scanned and
checked. In the second round, the full-texts of included
articles were read carefully and quality was assessed in the
last round. Two authors independently assessed the qual-
ity of the articles included and extracted the data. Differ-
ences were resolved by consensus.
Quality assessment
Quality assessment was conducted at the ‘study’ level,
i.e. each study was analyzed one by one. A checklist for
critical appraisal of economic evaluations [27] was used toevaluate the study quality. The checklist comprises 12 cri-
teria assessing the study design, outcomes and costs and
the extrapolation of the results of an economic evaluation.
An additional file shows this checklist in more detail (see
Additional file 1).
The criterion ‘applicable to local population’ was not in-
cluded in the assessment as we didn’t felt this was relevant
for the current study; i.e. 11 criteria were considered in
the end. In case studies showing cost savings, the absence
of an explicit incremental cost-effectiveness ratio (ICER)
was classified as adequate, since in that case no incremen-
tal ratio is necessary or meaningful.
Studies were subsequently included in the full review
if: 1) the outcomes and costs have been assessed as be-
ing credibly, 2) at least 6 of the 11 quality criteria were
rated as adequate or good; and 3) not more than three
quality criteria were assessed as being inadequate.
Data extraction
Data extraction was based on the 11 criteria included in
the quality assessment checklist which concerned: 1) basic
information of study design; 2) data on outcomes and
costs; and 3) results and conclusions. We grouped articles
into two groups, reflecting ACEIs and ARBs. The latter
group was subdivided into three subgroups in line with
the three mostly analyzed ARBs, irbesartan, losartan and
valsartan.
To make the results comparable across the studies,
cost-saving or ICER results were standardized to 2011
price levels, by applying the appropriate annual deflators
for each country, based on the statistics from the World
Bank [28]. Since the deflator data for Taiwan was not
available from the World Bank, cost data of this region
was not standardized. The original cost-saving result was
showed as reference.
All the currencies were converted to 2011 Euros,
based on the Euro rate as of June 30th, 2011 [29].
The results of selected studies were classified in 5 cat-
egories: 1) cost-saving: net life years or QALYs gained in
conjunction with ≥ €1,000 saved per patient as compared
with the comparison intervention; 2) almost cost-neutral:
net life years or QALYs gained, with < €1,000 saved per
patient; 3) very cost-effective: 0 < ICER ≤ €20,000; 4) cost-
effective: €20,000 < ICERs ≤ €40,000; 5) not cost-effective:
ICERs > €40,000. The classification was based on both
literature and suggestions in identified studies in this
review [30,31].
Results
Up to October 2011, 434 articles (141 articles from PubMed
and 293 articles from EMBASE) were identified. After
full-text checking, 32 articles were included into the qual-
ity assessment. After quality assessment, 30 articles were
finally included in this review (Figure 1). One of the





Articles retrieved for more 
detailed evaluation:
N=62
Articles met inclusion 
criteria and were original 
economic evaluations:
N=32
Titles or abstract that did 
not meet inclusion 
criteria:
N=372
Full-text articles that did 






Figure 1 Flow chart summarizing systematic study selection process.
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and only 4 criteria assessed as good. The other one
merely got 5 criteria rated as adequate among the 11 cri-
teria considered.
Among these 30 selected articles, in one article on
losartan for an Asian population [32] only the data from
Hong Kong were considered as the cost data from other
Asian countries or regions assessed seemed not to be of
adequate quality. Finally, 39 studies in different countries
or regions contained in these 30 articles were included
in the analysis.
Summary of selected studies
Table 2 summarizes the basic features of studies in-
cluded. All six ACEIs studies [33-38] were literature-
based evaluations which synthesized data from different
sources. All ARBs studies [32,39-62] were designed basedon specific trials. The Markov model was the most com-
mon decision analytic method used in these evaluations.
From the cost-effectiveness results, 37 out of 39 studies
indicated both ACEIs and ARBs were cost-saving compar-
ing with placebo/conventional treatment or amlodipine.
In the absence of clear cost savings, cost neutrality of
very favorable cost-effectiveness was achieved minimally.
No studies were identified with a direct cost-effectiveness
comparison between ACEIs and ARBs.
Design of selected studies
Key features of the design of the selected studies were
summarized in Table 3. Six studies of ACEIs [33-38]
were diverse in data sources, intervention and control
groups. The 33 studies on ARBs showed much more
consistency within each ARB drug class (losartan,
irbesartan and valsartan) regarding control and data











Data source Trial based 0 33 14 18 1
Literature based 6 0 0 0 0
Intervention and
control group
Comparing with placebo/conventional therapy 2 22 14 8 0
Comparing with other drugs 0 12 0 11 1
Comparing different strategies 4 10 0 10 0
Decision model Markov model 6 20 1 18 1
Weibull model 0 3 3 0 0
Regression method 0 10 10 0 0
Perspective Third party payer 4 33 14 18 1
Societal 2 0 0 0 0
CE results Cost-saving 5 32 13 18 1
Cost-neutral 0 1 1 0 0
Very cost-effective 1 0 0 0 0
Cost-effective 0 0 0 0 0
Not cost-effective 0 0 0 0 0
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ARBs.
ACEIs
Six studies [33-38] evaluated the cost-effectiveness of
ACEIs, all using a Markov model as the method for de-
cision modeling. The transition probabilities in these
Markov models, i.e. the sources and sizes of effectiveness
data in these studies, were diverse. All six studies ob-
tained their effectiveness data from more than one RCT
[63-67] or from meta-analyses [37,38]. Only one of the
studies [34] included a specific ACEI, enalapril, to com-
pare with placebo, while the other five studies treated
ACEIs as a group or drug class. ARBs were also included
in the analytic model as a substitute for ACEIs when pa-
tients got cough side-effect in the two articles written by
Adarkwah et al. [37,38].
ARBs
The 33 studies (included in 24 articles [32,39-61]) target-
ing ARBs have major similarities in study design. Four-
teen evaluations for losartan [32,39-47] were based on
The Reduction of Endpoints in Non-insulin Dependent
Diabetes Mellitus with the Angiotensin II Antagonist
Losartan (RENAAL) trial [62]. Eighteen evaluations of
irbesartan [48-60] used data from the Irbesartan in
Diabetic Nephropathy Trial (IDNT) [68] to assess the
cost-effectiveness for patients with type 2 diabetes
and overt nephropathy before 2004. Later the Irbesartan
in Reduction of Microalbuminuria-2 (IRMA-2) [69] trial
was added into the model to expand the progress of dia-
betic renal development from nephropathy back tothe onset of MiA. The only study for valsartan was based
on the MicroAlbuminuria Reduction With VALsartan
(MARVAL) study [70].
All 14 losartan studies can be subdivided into two
groups based on different time horizon. Eleven studies
[32,39-42,46,47] were within-trial analyses, while the
other three [43-45] extrapolated to beyond-trial time-
horizon analyses. Ten within-trial analyses [32,39-42,47]
used a straightforward method to calculate the effective-
ness and cost. In this method, the patient-days spent
in the stage of ESRD were estimated by subtracting
the area under curve (AUC) of the Kaplan-Meier survival
curve for time to the minimum of ESRD or all-cause
death for both groups in the trial. The costs of ESRD were
calculated by multiplying ESRD days and daily cost of
ESRD. Only one within-trial study [46] performed a
Markov model as the analytic method to evaluate the
cost-effectiveness. Three beyond-trial studies [43-45] used
a Weibull model to prolong the time horizon to lifetime.
Cumulative incidence of ESRD and life expectancy were
assessed as the effectiveness measurements.
Irbesartan for overt nephropathy was compared with
conventional treatment and amlodipine in five studies
[48-51]. These five studies were based on the IDNT trial
and a Markov model with five stages (from ‘overt nephrop-
athy’ via ‘double of serum creatinine’, ‘ESRD+ dialysis’ and
‘ESRD+ transplant’ to ‘death’) was developed to evaluate
life expectancy and lifetime cost. In particular, Palmer
et al. combined the IRMA-2 trial with the IDNT trial
and applied a seven-stage Markov model, extrapolating
the Markov model with a previous MiA state [48,49,51-60].
‘Early irbesartan’ (standard antihypertensive therapy plus
Table 3 Study design of economic evaluations on ACEIs and ARBs
Study, country/region Source of
effectiveness
data









‘Treat all’ strategya (1) Screen for MiAb; Markov model with 5 states 10 CEA & CUA (Life-years & QALYs)
(2) Screen for gross
proteinuriac.





Enalapril at the dose of 10 mg/
day
Placebo Markov model with 4 stages 25 CEA (Life years)










Markov model adding a cardiovascular
events component.
lifetime CEA & CUA (Life-years & QALYs)









No ACEI initiation in patients Markov model 8 CEA (CVD event avoided, life
saved, dialysis prevented,
composite endpoint avoided)




‘Treat all’ strategya (1) Screen for MiAb; Markov model with 5 states 50 CUA (QALY)
(2) Screen for MaAc;
(3) no-screening and
no-treatment alternative.




‘Treat all’ strategya (1) Screen for MiAb; Markov model with 5 states 50 CUA (QALY)
(2) Screen for MaAc.
ARBs
Losartan
Herman et al. 2003 US
[39]
RENAAL trial Losartan Placebod A regression-based method 3.5 / 4 CEA (Number of ESRD days)
Souchet et al. 2003
France [40]
RENAAL trial Losartan (initial daily dosing of
losartan was 50 mg, with the
possibility of titration to
100 mg/day)
Placebod A regression-based method 3.5 / 4 CEA (Number of ESRD days)
Burgess et al. 2004
Canada [41]
RENAAL trial Losartan Placebod A regression-based method 3.5 / 4 CEA (Number of ESRD days)
Szucs et al. 2004
Switzerland [42]
RENAAL trial Losartan (initial daily dosing of
losartan was 50 mg, with the
possibility of titration to
100 mg/day)
Placebod A regression-based method 3.5 / 4 CEA (Number of ESRD days)
Seng et al. 2005 Hong
Kong [32] (only data of
Hong Kong were
included)



















Table 3 Study design of economic evaluations on ACEIs and ARBs (Continued)
Arredondo et al. 2005
Mexico [43]
RENAAL trial Losartan Placebod A variation of the cumulative incidence
competing risk method / Weibull model
25 (life
time)
CEA (Cumulative incidence of
ESRD, life expectancy)




Weibull model life time CEA (Cumulative incidence of
ESRD, life expectancy)
Carides et al. 2006 US
[45]
RENAAL trial Losartan Placebod A cumulative incidence competing risk
method / Weibull model
25 (life
time)
CEA (Cumulative incidence of
ESRD, life expectancy)
Stafylas et al. 2007
Greece [46]
RENAAL trial Losartan (50–100 mg QD) Placebod Markov model with 6 states 3.5/4 CEA (Number of ESRD days)
de Portu et al. 2011
Italy, France, Germany,
Switzerland, US [47]
RENAAL trial Losartan Standard cared Standard methods by comparing the
economic outcomes deriving from
additional losartan to standard care vs
standard care alone
3.4 CEA (Number of ESRD days)
Irbesartan
Rodby RA et al. 2003
US [48]
IDNT trial Irbesartan titrated from 75 to
300 mg/day
(1) ‘Control’d; Markov model with 5 stages 25 CEA (Life expectancy)
(2) Amlodipine titrated from
2.5 to 10 mg/day.
Palmer AJ et al. 2003
Belgium, France [49]
IDNT trial Irbesartan titrated from 75 to
300 mg/day
(1) ‘Control’d; Markov model with 5 stages 25 CEA (Life expectancy)
(2) Amlodipine titrated from
2.5 to 10 mg/day.
Coyle D et al. 2004
Canada [50]
IDNT trial Irbessartan (1) Amlodipine; Markov model with 5 stages 25 CEA (Life expectancy)
(2) Standard cared
Palmer AJ et al. 2004
UK [51]
IDNT trial Irbesartan 300 mg per day (1) ‘Control’d; Markov model with 5 stages 25 CEA (Life expectancy)
(2) Amlodipine 10 mg per
day.




‘Early irbesartan’e (1) ‘Control’d; Markov model with 7 stages 25 CEA (Years free of ESRD,
cumulative incidence ESRD, life
expectancy)(2) ‘Late irbesartan’
f




‘Early irbesartan’e Standard antihypertensive
medicationsd
Markov model with 7 stages 25 CEA (Years free of ESRD,
cumulative incidence ESRD, life
expectancy)






initiated when patients had
developed MiA.
Markov model with 7 stages 25 CEA (Years free of ESRD,
cumulative incidence of ESRD, life
expectancy)




‘Early irbesartan’e (1) ‘Control’d; Markov model with 7 stages 25 CEA & CUA (Years free of ESRD,
life expectancy, QALY)
(2) ‘Late irbesartan’f




‘Early irbesartan’e ‘Placebo’d: standard
antihypertensive medications
Markov model with 7 stages 25 CEA (Years free of ESRD,




















Table 3 Study design of economic evaluations on ACEIs and ARBs (Continued)
initiated when patients
developed MiA.




‘Early irbesartan’e (1) ‘Control’d; Markov model with 7 stages 25 CEA (Years free of ESRD,
cumulative Incidence of ESRD, life
expectancy)(2) ‘Late irbesartan’
f




‘Early irbesartan’e (1) ‘Late irbesartan’f; Markov model with 7 stages 25 CEA (Life expectancy)
(2) ‘Conventional’d




‘Early irbesartan’e (1) ‘Standard’d; Markov model with 7 stages 25 CEA (Life expectancy, number of
years free of ESRD, cumulative
incidence of ESRD)(2) ‘Late irbesartan’
f;
(3) ‘Late amlodipine’g






‘Early irbesartan’e (1) ‘Standard’d; Markov model with 7 stages 25 CEA (Cumulative incidence of
ESRD, number of days in dialysis,





Smith DG et al. 2004 US
[61]
MARVAL study Valsartan Amlodipine Markov model with 7 stages 8 CUA (Quality-adjusted survival)
a: no screening was performed at all and patients started on ACEI therapy at the time of diagnosing type 2 diabetes.
b: patients were screened for MiA once a year and ACEI treatment was started if the test result is positive.
c: patients were screened for MaA once a year and ACEI treatment was started if the test result is positive.
d: standard antihypertensive therapy alone, excluding the use of ACEIs, ARBs.
e: standard antihypertensive therapy plus administration of irbesartan 300 mg/d at the onset of MiA.
f: standard antihypertensive therapy plus administration of irbesartan 300 mg/d once the patients reach the advanced diabetic nephropathy stage.
g: standard antihypertensive therapy plus administration of amlodipine titrated from 5 to 10 mg/d once the patients reach the advanced diabetic nephropathy stage.
UERNN = Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus; LEAPP = Long-term stabilizing effect of angiotensin-converting enzyme
inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients; EADN = The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy; LEAN = Long-term renoprotective
effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus; H-MH = Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the
HOPE study and MICRO-HOPE substudy; HOPE = The Heart Outcomes Prevention Evaluation; RENAAL = The reduction of endpoints in non-insulin dependent diabetes mellitus with the angiotensin II antagonist losartan;
IDNT = The irbesartan in diabetic nephropathy trial; IMRA-2 = The irbesartan in reduction of microalbuminuria-2; MARVAL = The microalbuminuria reduction with valsartan.
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conventional therapy and ‘late irbesartan’ or ‘late amlodi-
pine’ (standard antihypertensive therapy plus administra-
tion of irbesartan/amlodipine once the patients reach the
advanced diabetic nephropathy stage).
Cost-effectiveness of Valsartan [61] was evaluated in one
study using amlodipine as the control. A Markov model
with seven stages was designed and QALYs were calcu-
lated as the effectiveness results.
Cost-effectiveness results
The key features and main results of all included evalua-
tions are summarized in Table 4.
ACEIs
Of the six ACEIs’ studies, two [33,35] adopted a societal
perspective. This contained additional cost analyses in-
cluding productivity gains and losses, caregiver time costs.
The other four [34,36-38] took the third party payer/
health care perspective including only direct costs of ne-
phropathy, ACEIs or other related treatment such as those
for cardiovascular disease (CVD). All studies except one
[33] favored ACEIs due to the cost-saving results. The
exception was the evaluation from Golan et al. [33],
showing that compared to ‘screen for MiA’ (patients were
screened for MiA once a year and ACEI treatment was
started if the test result is positive), the ‘treat all’ strategy
with ACEIs (no screening was performed at all and pa-
tients started on ACEI therapy at the time of diag-
nosing type 2 diabetes) raised the costs by $300, but
the results still supported ‘treat all’ strategy as very
cost-effective. –It should be noted that these positive
results were based on the comparison between ACEIs
and no blood pressure (BP) control treatment but not
other BP control interventions.
ARBs
Based on the RENAAL trial, all the results over 3.5 years
indicated losartan was cost-saving or cost-neutral (Hong
Kong) [32] comparing to placebo/conventional therapy.
The cost savings per patients ranged from €2,079 in
Greece [46] to €4,641 in France [47]. When the time
horizon was prolonged to lifetime or 25 years, beyond-
trial studies showed that the net cost savings by adding
losartan to conventional therapy were €9,182 in UK [44],
€1,861 in Mexico [43] and €22,757 in U.S [45].
For irbesartan, results consistently showed cost-savings
comparing with conventional therapy or amlodipine, even
when already started at the onset of MiA. Such early start
of irbesartan would economically be even more attractive
as compared with late irbesartan starting at overt ne-
phropathy. The five studies [48-51] based on the IDNT
trial demonstrated that irbesartan for overt nephropathy
could prolong life expectancy with 0.43 years (Canada)[50] to 0.74 years (U.S.) [48] and save €7,075 (U.K.) [51] to
€19,132 (France) [49] per patient comparing with control
over 25 years. When the MiA stage was introduced into
the model, early irbesartan remained cost-saving at €2,564
in Hungary [56] to €57,871 in Canada [58] compared with
control, being more cost-saving than late irbesartan.
The only study for valsartan [61] also supported the
using of ARBs in patients with type 2 diabetes and MiA
because of saving QALYs and costs. Over 8 years, valsar-
tan treatment had 0.555 discounted QALYs advantage
over amlodipine with savings at €30,424 compared to
amlodipine.
Discussion
To our knowledge, this is the first review that summa-
rizes all information on the cost-effectiveness of both
ACEIs and ARBs. Our systematic review confirms earlier
results evidencing the cost-saving potentials of ARBs for
type 2 diabetic patients with nephropathy compared
with conventional therapy excluding a RAAS inhibitor.
Also, our review shows that such potentials might even
stronger exist in early treatments prior to the stage of
nephropathy, for example, in the MiA-stage. In addition,
we found similar cost-saving results for ACEIs due to
avoidance of ESRD in combination with prolonging life
expectancy. Differences in cost effectiveness of ACEI
versus ARB could not be solidly established because of
differences in model design, time horizon and country
setting among all included studies and lack of head-to-
head comparisons in economic evaluations. Yet, cost-
saving potentials were unequivocally assessed for both
drug groups.
Cost-effectiveness of ACEIs
The number of articles concerning ACEIs was limited
compared with the number for ARBs. The reason for
not basing studies on single clinical trials may be related
to the chronology of ACEIs being available on the market,
i.e. the 1980s, before the ARBs. The relevance of CVD in
diabetes became only clear in 1990s when the benefits of
RAAS inhibitors started also to become clear for diabetic
patients. From the six articles included in this review,
ACEIs were cost-saving in articles published after 2000s
[34-38] and not cost saving (but very cost-effective) in the
only one article before 2000s [33]. This may be explained
by the patent protection of ACEIs which became generic
in the late of 1990s.
Three articles [33,37,38] combined screening for MiA
or MaA as the start time point of ACEIs treatment in
their analyses. Previous studies of screening for albumin-
uria with subsequent ACEIs treatment on cardiovascular
and renal diseases also support the conclusions on favor-
able cost-effectiveness and early treatments. Atthobari
et al. [71] found that the estimated cost-effectiveness of



















3 3 Societal The cost of ESRD (dialysis &
transplant), ACEIs and
screening
15.63 years/11.82 QALYs with ‘treat all’, ‘Treat all’ vs ‘scre for
MiA’: $300a






15.59 years/11.78 QALYs with ‘screen for
MiA’, 15.39 years/11.59 QALYs with




8 8 Not mentioned The cost of ESRD
(haemodialysis) and ACEI
9.04 years with enalapril, 7.54 years with
control
-$1,198 [1999] -€1,269 Cost saving
[Enalapril]
Rosen et al. 2005
US [35]
3 3 Medicare and
societal
(1) Medicare perspective: direct
medical costs and future health
care costs.
10.55 years/8.36 QALYs with Medicare
first-dollar coverage of ACEIs, 10.30 years
/8.13 QALYs with at the time practice










3 3 Health payer Direct medical costs of





















3 3 the German
statutory health
insurance
The cost of ESRD (dialysis &
transplant), ACEIs, ARBs and
screening
15.21 QALYs with ‘treat all’, ‘Treat all’ vs. ‘pla o’:
-€16,024 [2006]




15.14 QALYs with ‘screen for MiA’, 14.83





1.5 4 Health care The cost of ESRD (dialysis &
transplant), ACEIs, ARBs and
screening
19.63 QALYs with ‘treat all’, 19.54 QALYs
with ‘screen for MiA’, 19.15 with ‘screen
for MaA’
‘Treat all’ vs. ‘scr for
MiA’: -€2,719, ‘tr all’
vs. ‘screen for M :
-€12,356 [2010]
‘Treat all’ vs. ‘screen
for MiA’: -€2,749, ‘treat







et al., 2003 US
[39]
none 3 Health care
system
The cost of ESRD
(hemodialysis) and losartan
therapy
Over 3.5 years: - 22
[2001]
Over 3.5 years: -€3,306 Cost saving
[losartan]
Souchet T et al.,
2003 France [40]
none 8.1%b French health
care system
The cost of ESRD (dialysis) and
losartan therapy
Over 3.5 years: - 63
[2002]






























Table 4 Main results of economic evaluations on ACEIs and ARBs (Continued)
Burgess ED et al.,
2004 Canada [41]
none none Health care
system
The cost of ESRD (dialysis
& transplant) and losartan
therapy
Over 3.5 years: -$3,675a Over 3.5 years: -€3,368 Cost saving
[losartan]
Szucs TD et al.,
2004 Switzerland
[42]
none none Swiss health
care payer
The cost of ESRD (dialysis
& transplant) and losartan




Over 3.5 years: -€3,660 Cost saving
[losartan]
Seng WK et al.,
2005 Hong Kong
[32] (only data of
Hong Kong were
included)
3 3 Health care
system
The cost of ESRD (dialysis) and
losartan therapy





3 3 Health care
system
The cost of ESRD (dialysis),
diabetes and losartan therapy
0.697 life years gained for losartan -M$24,073 [2004] -€1,861 Cost saving
[losartan]
Vora J et al., 2005
UK [44]
3.5 3.5 The UK National
Health Service
(NHS)
The cost of ESRD (dialysis) and
losartan therapy
7.82 life years with losartan, 7.38 life
years with placebo (0.44 life years
gained for losartan)
-£6,622 [2004] -€9,182 Cost saving
[losartan]
Carides GW et al.,
2006 US [45]
3 3 Health care
system
The cost of ESRD (dialysis),
diabetes and losartan therapy
0.697 life years gained for losartan -$24,632 [2002] -€22,757 Cost saving
[losartan]
Stafylas PC et al.,
2007 Greece [46]
3 3 The Greek
social insurance
system
The cost of ESRD (dialysis &




Over 3.5 years: -€2,079 Cost saving
[losartan]





The cost of ESRD
(hemodialysis) and losartan
therapy
-€3,602.98 [2009] -€3,664 Cost saving
[losartan]




The cost of ESRD
(hemodialysis) and losartan
therapy
-€4,531.35 [2009] -€4,641 Cost saving
[losartan]





The cost of ESRD
(hemodialysis) and losartan
therapy
-€3,019.66 [2009] -€3,062 Cost saving
[losartan]





The cost of ESRD
(hemodialysis) and losartan
therapy
-€3,949.50 [2009] -€3,977 Cost saving
[losartan]
de Portu S et al.,
2011 US [47]




The cost of ESRD
(hemodialysis) and losartan
therapy
-€3,855.50 [2009] -€4,007 Cost saving
[losartan]
Irbesartan
Rodby RA et al.,
2003 US [48]
3 3 Health care
system




8.225 years with irbesartan, 7.484 years
with control (0.741 years gained for
irbesartan)




















Table 4 Main results of economic evaluations on ACEIs and ARBs (Continued)
Palmer AJ et al.,
2003 Belgium
[49]





The cost of ESRD (dialysis &
transplant) and irbesartan &
concomitant antihypertensive
drugs
8.57 years with irbesartan, 7.95 years
with control (0.62 years gained for
irbesartan)
-€11,885 [2002] -€14,231 Cost saving
[irbesartan]
Palmer AJ et al.,
2003 France [49]
3 3 Social security The cost of ESRD (dialysis &
transplant) and irbesartan &
concomitant antihypertensive
drugs
8.58 years with irbesartan, 7.97 years
with control (0.61 years gained for
irbesartan)
-€16,345 [2002] -€19,132 Cost saving
[irbesartan]
Coyle D et al.,
2004 Canada [50]
5 5 Third party
payer
The cost of ESRD (dialysis &
transplant), irbesartan &
concomitant antihypertensive
drugs and other medical costs
6.80 years with irbesartan, 6.37 years
with control (0.43 years gained for
irbesartan)
-CAD12,564 [2001] -€11,457 Cost saving
[irbesartan]
Palmer AJ et al.,
2004 UK [51]
1.5 6 National Health
Service (NHS)
payer
The cost of ESRD (dialysis &
transplant) and irbesartan &
concomitant antihypertensive
drugs
0.58 years gained for irbesartan vs
control
-£4,978a -€7,075 Cost saving
[irbesartan]
Palmer AJ et al.,
2004 US [52]
3 3 Third party
reimbursement
The cost of ESRD (dialysis &
transplant) and irbesartan
11.46 years with ‘early irbesartan’,
10.54 years with ‘late irbesartan’,
10.50 years with control (0.96 years











Palmer AJ et al.,
2005 Spain [53]
3 3 Third party
payer
The cost of ESRD (dialysis &
transplant) and irbesartan
12.37 years with ‘early irbesartan’,
11.53 years with control (0.84 years
gained for irbesartan)
-€11,082a -€12,971 Cost saving [early
irbesartan]
Palmer AJ et al.,
2006 Switzerland
[54]
5 5 Third party
Swiss health
insurance payer
The cost of ESRD (dialysis &
transplant) and irbesartan
10.37 years with ‘early irbesartan’,
9.80 years with control (0.57 years
gained for irbesartan)
-CHF21,487 [2003] -€19,257 Cost saving [early
irbesartan]
Palmer AJ et al.,
2006 France [55]




The cost of ESRD (dialysis &
transplant) and irbesartan
12.17 years /10.55 QALYs with ‘early
irbesartan’, 11.27 years /9.58 QALYs with
‘late irbesartan’, 11.23 years /9.52 QALYs
with control (0.94 years /1.03 QALYs


















The cost of ESRD (dialysis &
transplant) and irbesartan
8.16 years with ‘early irbesartan’,
7.62 years with control (0.54 years
gained for irbesartan)








The cost of ESRD (dialysis &
transplant) and irbesartan
11.00 years with ‘early irbesartan’,
10.20 years with ‘late irbesartan’,
10.18 years with control (0.82 years

















All direct costs, including the
costs of health, social services,
long-term care.
11.52 years with ‘early irbesartan’,
11.06 years with ‘late irbesartan’,
10.90 years with control (0.62 years
gained for irbesartan vs control)
‘Early irbesartan’ vs.
control: -CAD68,400,


























Table 4 Main results of economic evaluations on ACEIs and ARBs (Continued)








The cost of ESRD (dialysis &
transplant) and irbesartan
12.003 years with ‘early irbesartan’,
11.332 years with ‘late irbesartan’,
11.223 years with control (0.780 years












5 5 Third party
payer
The cost of ESRD (dialysis &
transplant) and irbesartan
‘Early irbesartan’ strategy had the longest












Medical care costs including
costs of study drugs, routine
health care services, and
aggregate estimates of medical
care associated with the
various health states.
6.390 QALYs with valsartan, 5.835 QALYs
with amlodipine (0.555 QALYs gained for
valsartan)
-$32,412 [2001] -€30,424 Cost saving
[valsartan]
a: In which year the value of money standardized was not clear. It was assumed to be one year before the publication.
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http://www.biomedcentral.com/1471-2369/15/15screening for albuminuria with ACEIs treatment was ap-
proximately €16,700/LYG (2006 value) for subjects with a
urinary albumin excretion >15 mg/d compared with no
screening when adopting the Dutch health care perspec-
tive. This was in accordance with the analyses from
Boersma C et al. [72] suggesting the potentially favorable
cost-effectiveness of population-based screening for MiA
compared with other alternatives. Notably, however the
latter two articles were for prevention of cardiovascular
and renal events in the general population, not particularly
for diabetic patients.
Cost-effectiveness of ARBs
The pharmacoeconomic results of ARBs for renal disease
in patients with type 2 diabetes were reviewed previously.
Ravera et al. [22] and Boersma et al. [21] reviewed the eco-
nomic evaluations for ARBs and concluded that eval-
uations derived from RENAAL, IDNT, IRMA-2 and
MARVAL all suggested ARBs to be cost saving com-
pared with conventional therapy in type 2 diabetes patients
with nephropathy. Postma & de Zeeuw [26] reviewed the
economic benefits of preventing ESRD in patients with
type 2 diabetes. They divided the RAAS drug treatment
into early and late interventions and concluded that early
intervention strategies appear more effective in reducing
the risk and the pharmacoeconomic profiles of early inter-
vention clearly outweigh those of late intervention.
From our literature search, there were various eco-
nomic evaluations on the ARBs losartan, irbesartan and
valsartan. There were little differences between studies
in each subgroups of ARBs concerning the analysis
model, time horizon and measurement of costs and ben-
efits. Although the results varied in different studies and
countries, all conclusions supported ARBs as a cost-
saving choice.
Differences in economic evaluations of ACEIs and ARBs
The trials referred to in the studies included in this review
had different patient characteristics and treatment strat-
egies. Patients enrolled in ACEIs trials were mainly normo-
tensive, while patients enrolled in ARBs trials were mainly
hypertensive. Trails with ACEIs had no equal BP control
in placebo groups, whereas trials with ARBs had active BP
control in placebo groups. Differences in time horizons
used for ACEIs and ARBs present another reason hinder-
ing comparison of cost effectiveness between these two
drug classes.
Referring to the analytic models, the transition probabil-
ities between two states in the Markov model adopted in
these ACEIs studies were from different trials, which may
weaken the internal validity of the simulation model used
and effectiveness results generated. The analytic models
used for ARBs were relatively consistent in their strong
alignment to the clinical trials available. Similar methodswere adjusted to different country settings. This enhanced
similarity in cost-effectiveness results of the same ARB
drug in different countries. One might argue that the ma-
jority of economic evaluations for losartan were cost ana-
lyses with existing trial-based effectiveness as the building
block.
Differences in evaluation results of ACEIs and ARBs
Previous reviews [18-26] of ACEIs and ARBs didn’t
summarize the differences between ACEIs and ARBs in
the absence of direct comparisons between ARBs and
ACE inhibitors in terms of cost-effectiveness. In this re-
view, also no valid comparison between ACEIs and ARBs
is possible regarding cost-effectiveness.
In the lifetime treatment for diabetic nephropathy, cost
of dialysis when patients develop to ESRD plays an im-
portant role in the burden of disease. Comparing to the
cost of ESRD, the cost of drugs comprise a relatively low
proportion in the total disease expenditure. As ACEIs and
ARBs both can delay the deterioration of kidney function
to save huge cost due to treatment, results of the economic
evaluations included in this review are all pointing into the
same direction that these two drug classes are cost-saving
or very cost-effective. Furthermore, most ARBs now are
available in generic forms and thus cheaper than when
these evaluations were performed, which makes ARBs and
ACEIs more similar in both effectiveness and cost. There-
fore, similar cost-effectiveness result between ACEIs and
ARBs can be hypothesized and results in this review
strengthen the relevance of the choice made in guidelines
[14,18] of recommending ACEIs or ARBs as both pre-
senting cost-effective choices for patients with diabetic
nephropathy.
Limitations
In our review, although the standardized results showed
an overview of the cost-effectiveness results of ACEIs and
ARBs, to calculate a synthesized economic evaluation re-
sult of ACEIs and ARBs using the cost-effectiveness re-
sults in different economic evaluations could not validly
be done, given all the aforementioned differences. This is
mainly due to two limitations. Firstly, the baseline charac-
teristics of the populations varied in the studies included.
Secondly, the effectiveness outcomes varied in different
studies.
Various selected studies in this review were strongly
based on clinical trial settings. Trials are the gold standard
for internal validity, but the problem is the lack of external
validity [73]. The challenges and the need to include the
real-world evidence in economic evaluations has been
pointed out by pharmacoeconomic researchers [74]. In
the mentioned cost-effectiveness analysis of screening for
MiA by Boersma C et al. [72], they used population-based
observational data, rather than efficacy data from clinical
Huang et al. BMC Nephrology 2014, 15:15 Page 15 of 17
http://www.biomedcentral.com/1471-2369/15/15trials. The obvious problem is these settings is how to ad-
just for potential confounders and this requires careful
consideration. For example, the extent in which data cover
the population actually using the drugs, the adverse drug
events and the drug use pattern all influence the results
of effectiveness analysis. Findings from drug utilization
studies relevant to aspects involving (non-)adherence or
safety issues should be used in future analyses of drugs’
(cost-)effectiveness. In our efforts to extract some safety
information from our current included studies, only two
articles [37,38] mention a higher risk of dry cough associ-
ated with ACE inhibitors and discuss whether this side ef-
fect would influence the cost-effectiveness of ACEIs. This
systematic review illustrates the lack of inclusion of obser-
vational data in the pharmacoeconomic evaluations so far
performed.
Conclusion
Considering the current evidence, both ACEIs and ARBs
are cost-saving compared with conventional therapy ex-
cluding a RAAS inhibitors. There is a lack of evidence in
direct comparison of these two drug classes in consistent
economic evaluations. Because of the limited external
validity in using RCT data and the simulation results de-
rived from trial-based analytical models, observational
data should be used to confirm these trial-based cost-
effectiveness analyses’ results.Additional file
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